| Year |
Citation |
Score |
| 2018 |
Emberley ED, Bennett M, Chen J, Gross M, Huang T, Makkouk A, Marguier G, Pan A, Spurlock SM, Steggerda S, Parlati F. Abstract 3509: The glutaminase inhibitor CB-839 synergizes with CDK4/6 and PARP inhibitors in pre-clinical tumor models Cancer Research. 78: 3509-3509. DOI: 10.1158/1538-7445.Am2018-3509 |
0.425 |
|
| 2017 |
Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, Janes JR, Li W, MacKinnon AL, Makkouk A, Marguier G, Murray PJ, Neou S, Pan A, Parlati F, Rodriguez MLM, et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. Journal For Immunotherapy of Cancer. 5: 101. PMID 29254508 DOI: 10.1186/S40425-017-0308-4 |
0.386 |
|
| 2017 |
Papadopoulos KP, Tsai FY, Bauer TM, Muigai L, Liang Y, Bennett MK, Orford KW, Fu S. CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors. Journal of Clinical Oncology. 35: 3005-3005. DOI: 10.1200/Jco.2017.35.15_Suppl.3005 |
0.406 |
|
| 2017 |
DeMichele A, Harding J, Telli M, Münster P, McKay R, Iliopoulos O, Whiting S, Orford K, Bennett M, Mier J, Owonikoko T, Patel, Kalinsky K, Carvajal R, Infante J, et al. Abstract P6-11-05: Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-11-05 |
0.359 |
|
| 2016 |
Meric-Bernstam F, Tannir NM, Mier JW, DeMichele A, Telli ML, Fan AC, Munster PN, Carvajal RD, Orford KW, Bennett MK, Iliopoulos O, Owonikoko TK, Patel MR, McKay R, Infante JR, et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). Journal of Clinical Oncology. 34: 4568-4568. DOI: 10.1200/Jco.2016.34.15_Suppl.4568 |
0.351 |
|
| 2016 |
DeMichele A, Harding JJ, Telli ML, Munster PN, McKay R, Iliopoulos O, Orford KW, Bennett MK, Mier JW, Owonikoko TK, Patel MR, Carvajal RD, Meric-Bernstam F, Infante JR. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC). Journal of Clinical Oncology. 34: 1011-1011. DOI: 10.1200/Jco.2016.34.15_Suppl.1011 |
0.406 |
|
| 2016 |
Steggerda SM, Bennett M, Chen J, Emberley E, Gross M, Huang T, Li W, MacKinnon A, Makkouk A, Marguier G, Neou S, Pan A, Wang T, Works M, Zhang J, et al. Abstract B045: Arginase inhibitor CB-1158 elicits immune-mediated antitumor responses as a single agent and in combination with other immunotherapies Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B045 |
0.42 |
|
| 2016 |
Works M, Bennett M, Chen J, Emberley E, Huang T, Janes J, Li W, Mackinnon A, Marguier G, Neou S, Pan A, Parlati F, Rodriguez M, Steggerda S, Wang T, et al. Abstract 552: Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response Cancer Research. 76: 552-552. DOI: 10.1158/1538-7445.Am2016-552 |
0.401 |
|
| 2016 |
Emberley E, Bennett M, Chen J, Gross M, Huang T, Li W, Mackinnon A, Pan A, Rodriguez M, Steggerda S, Wang T, Zhang J, Zhang W, Parlati F. CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitors European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)32969-0 |
0.374 |
|
| 2016 |
Steggerda S, Bennett M, Chen J, Emberley E, Gross M, Huang T, Li W, MacKinnon A, Makkouk A, Marguier G, Neou S, Pan A, Wang T, Works M, Zhang J, et al. Arginase inhibitor CB-1158 elicits immune-mediated anti-tumor responses as a single agent and enhances the efficacy of other immunotherapies European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)32888-X |
0.344 |
|
| 2015 |
Vogl DT, Younes A, Stewart K, Orford KW, Bennett M, Siegel D, Berdeja JG. Phase 1 Study of CB-839, a First-in-Class, Glutaminase Inhibitor in Patients with Multiple Myeloma and Lymphoma Blood. 126: 3059-3059. DOI: 10.1182/Blood.V126.23.3059.3059 |
0.348 |
|
| 2015 |
Wang ES, Frankfurt O, Orford KW, Bennett M, Flinn IW, Maris M, Konopleva M. Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia Blood. 126: 2566-2566. DOI: 10.1182/Blood.V126.23.2566.2566 |
0.387 |
|
| 2015 |
MacKinnon AL, Bennett M, Gross M, Janes J, Li W, Rodriquez M, Wang T, Zhang W, Parlati F. Metabolomic, Proteomic and Genomic Profiling Identifies Biomarakers of Sensitivity to Glutaminase Inhibitor CB-839 in Multiple Myeloma Blood. 126: 1802-1802. DOI: 10.1182/Blood.V126.23.1802.1802 |
0.405 |
|
| 2015 |
MacKinnon A, Bennett M, Emberley E, Gross M, Janes J, Lewis E, Pan A, Rodriguez M, Shwonek P, Wang T, Yang J, Zhao F, Parlati F. Abstract P1-08-07: A novel pharmacodynamic assay to measure glutaminase inhibition following oral administration of CB-839 in triple negative breast cancer biopsies Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-08-07 |
0.413 |
|
| 2015 |
Rodriguez M, Zhang W, Bennett M, Emberley E, Gross M, Janes J, MacKinnon A, Pan A, Steggerda S, Works M, Parlati F. Abstract 4711: CB-839, a selective glutaminase inhibitor, synergizes with signal transduction pathway inhibitors to enhance anti-tumor activity Cancer Research. 75: 4711-4711. DOI: 10.1158/1538-7445.Am2015-4711 |
0.436 |
|
| 2015 |
Meric-Bernstam F, DeMichele A, Telli ML, Munster P, Orford KW, Demitri GD, Schwartz GK, Iliopoulos O, Mier JW, Owonikoko TK, Bennett MK, Patel MR, Infante JR, Harding JJ. Abstract C49: Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C49 |
0.406 |
|
| 2015 |
Gross M, Chen J, Emberley E, Janes J, Li W, Mackinnon A, Pan A, Parlati F, Rodriguez M, Steggerda S, Wang T, Works M, Zhang J, Zhang W, Bennett M. Abstract A195: CB-1158 inhibits the immuno-oncology target arginase and causes an immune mediated anti-tumor response Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A195 |
0.426 |
|
| 2014 |
Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, Mackinnon AL, Parlati F, Rodriguez ML, Shwonek PJ, Sjogren EB, ... ... Bennett MK, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Molecular Cancer Therapeutics. 13: 890-901. PMID 24523301 DOI: 10.1158/1535-7163.Mct-13-0870 |
0.394 |
|
| 2014 |
Parlati F, Gross M, Janes J, Lewis E, MacKinnon A, Rodriguez M, Shwonek P, Bennett M. Glutaminase Inhibitor CB-839 Synergizes with Pomalidomide in Preclinical Multiple Myeloma Models Blood. 124: 4720-4720. DOI: 10.1182/Blood.V124.21.4720.4720 |
0.432 |
|
| 2014 |
Mackinnon A, Bennett M, Rodriguez M, Parlati F. Biomarkers of Response to the Glutaminase Inhibitor CB-839 in Multiple Myeloma Cells Blood. 124: 3429-3429. DOI: 10.1182/Blood.V124.21.3429.3429 |
0.384 |
|
| 2014 |
MacKinnon AL, Bennett MK, Gross MI, Janes JR, Lewis ER, Rodriguez MLM, Shwonek PJ, Taotao W, Yang J, Zhao F, Parlati F. Abstract 966: Novel pharmacodynamic assays to measure glutaminase inhibition following oral administration of CB-839 Cancer Research. 74: 966-966. DOI: 10.1158/1538-7445.Am2014-966 |
0.418 |
|
| 2014 |
Parlati F, Demo SD, Gross MI, Janes JR, Lewis ER, MacKinnon AL, Rodriguez MLM, Shwonek PJ, Wang T, Yang J, Zhang D, Zhao F, Bennett MK. Abstract 1416: CB-839, a novel potent and selective glutaminase inhibitor, has broad antiproliferative activity in cell lines derived from both solid tumors and hematological malignancies Cancer Research. 74: 1416-1416. DOI: 10.1158/1538-7445.Am2014-1416 |
0.413 |
|
| 2013 |
Parlati F, Bromley-Dulfano S, Demo S, Janes J, Gross M, Lewis E, MacKinnon A, Rodriguez M, Yang J, Zhao F, Bennett M. Antitumor Activity Of The Glutaminase Inhibitor CB-839 In Hematological Malignances Blood. 122: 4226-4226. DOI: 10.1182/Blood.V122.21.4226.4226 |
0.446 |
|
| 2013 |
Demo S, Chernov-Rogan T, Gross M, Janes J, Kawas R, Lewis E, Parlati F, Rodriguez H, Rodriguez M, Yang J, Zhao F, Richardson A, Bennett MK. Abstract 5604: Preclinical antitumor activity of novel small molecule glutaminase inhibitors in triple-negative breast cancer. Cancer Research. 73: 5604-5604. DOI: 10.1158/1538-7445.Am2013-5604 |
0.408 |
|
| 2013 |
Parlati F, Chernov-Rogan T, Demo S, Gross M, Janes J, Kawas R, Lewis E, Rodriguez H, Rodriguez M, Yang J, Zhao F, Richardson A, Bennett MK. Abstract 1877: Anti-tumor activity of novel, potent, selective and orally-bioavailable glutaminase inhibitors. Cancer Research. 73: 1877-1877. DOI: 10.1158/1538-7445.Am2013-1877 |
0.436 |
|
| 2013 |
Gross M, Budczies J, Demo S, Janes J, Lewis E, Parlati F, MacKinnon A, Rodriguez M, Yang J, Zhao F, Richardson A, Denkert C, Fiehn O, Bennett M. Abstract P2-09-03: Antitumor activity of the glutaminase inhibitor, CB-839, in triple-negative breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P2-09-03 |
0.345 |
|
| 2011 |
Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1873-82. PMID 21752943 DOI: 10.1124/Dmd.111.039164 |
0.306 |
|
| 2011 |
Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2734-43. PMID 21364033 DOI: 10.1158/1078-0432.Ccr-10-1950 |
0.4 |
|
| 2009 |
Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD, Bennett MK. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 114: 3439-47. PMID 19671918 DOI: 10.1182/Blood-2009-05-223677 |
0.417 |
|
| 2009 |
Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nature Medicine. 15: 781-7. PMID 19525961 DOI: 10.1038/Nm.1978 |
0.327 |
|
| 2009 |
Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlati F, Ring E, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). Journal of Medicinal Chemistry. 52: 3028-38. PMID 19348473 DOI: 10.1021/Jm801329V |
0.412 |
|
| 2009 |
Muchamuel T, Kapur S, Kirk CJ, Jiang J, Lee S, Bennett MK, Lewis E, Yang J, Jumaa M, Ring E, Phiasivongsa P, Zhou H, Wang Z. Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals. Blood. 114: 4910-4910. DOI: 10.1182/Blood.V114.22.4910.4910 |
0.394 |
|
| 2009 |
Vij R, Wang L, Orlowski RZ, Stewart AK, Jagannath S, Lonial S, Trudel S, Jakubowiak AJ, Belch A, Alsina M, Bahlis NJ, Le MH, Cruickshank S, Bennett MK, Molineaux S, et al. Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects. Blood. 114: 430-430. DOI: 10.1182/Blood.V114.22.430.430 |
0.313 |
|
| 2009 |
Siegel D, Wang L, Orlowski RZ, Kaufman JL, Stewart AK, Kukreti V, Alsina M, Jakubowiak AJ, Jagannath S, McDonagh KT, Belch A, Bahlis NJ, Shustik C, Le MH, Kunkel L, ... Bennett MK, et al. PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort. Blood. 114: 303-303. DOI: 10.1182/Blood.V114.22.303.303 |
0.306 |
|
| 2009 |
Wang L, Siegel D, Kaufman JL, Stewart AK, Jakubowiak AJ, Alsina M, Kukreti V, Bahlis NJ, McDonagh KT, Belch A, Sebag M, Gabrail N, Le MH, Bennett MK, Kunkel L, et al. Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM). Blood. 114: 302-302. DOI: 10.1182/Blood.V114.22.302.302 |
0.328 |
|
| 2009 |
Arastu-Kapur S, Ball AJ, Anderl JL, Bennett MK, Kirk CJ. Neurodegeneration Induced by Bortezomib Exposure in Vitro Occurs Via Proteasome Independent Mechanisms. Blood. 114: 2859-2859. DOI: 10.1182/Blood.V114.22.2859.2859 |
0.417 |
|
| 2009 |
Suzuki E, Demo S, Arastu-Kapur S, Kirk CJ, Bennett MK. Bortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to Carfilzomib. Blood. 114: 2852-2852. DOI: 10.1182/Blood.V114.22.2852.2852 |
0.392 |
|
| 2009 |
Trudel S, Lee S, Kirk CJ, Gabrail N, Lonial S, Wang L, Orlowski RZ, Kukreti V, Stewart AK, Jagannath S, McDonagh KT, Buadi F, Zonder JA, Bennett MK. Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients. Blood. 114: 1845-1845. DOI: 10.1182/Blood.V114.22.1845.1845 |
0.399 |
|
| 2009 |
Jiang J, Kirk CJ, Muchamuel T, Swinarski D, Bennett MK. Abstract B104: The orally bioavailable proteasome inhibitor PR‐047 inhibits metastasis in a mouse mammary carcinoma model Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B104 |
0.402 |
|
| 2008 |
Muchamuel T, Aujay M, Bennett MK, Dajee M, Demo S, Kirk CJ, Fang Y, Jiang J, Lewis E, Lu Y, Laidig G, Parlati F, Shields J, Sun Cm, Yang J, et al. Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome Blood. 112: 3671-3671. DOI: 10.1182/Blood.V112.11.3671.3671 |
0.431 |
|
| 2008 |
Kirk CJ, Jiang J, Muchamuel T, Dajee M, Swinarski D, Aujay M, Bennett MK, Yang J, Lewis E, Laidig G, Molineaux CJ. The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration Blood. 112: 2765-2765. DOI: 10.1182/Blood.V112.11.2765.2765 |
0.373 |
|
| 2008 |
Arastu-Kapur S, Shenk K, Parlati F, Bennett MK. Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and Carfilzomib Blood. 112: 2657-2657. DOI: 10.1182/Blood.V112.11.2657.2657 |
0.406 |
|
| 2007 |
Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, ... ... Bennett MK, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research. 67: 6383-91. PMID 17616698 DOI: 10.1158/0008-5472.Can-06-4086 |
0.422 |
|
| 2007 |
Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 110: 3281-90. PMID 17591945 DOI: 10.1182/Blood-2007-01-065888 |
0.4 |
|
| 2007 |
Parlati F, Aujay M, Bedringaas SL, Demo S, Gjertsen B, Goldstein E, Jiang J, Kirk C, Laidig G, Lorens J, Lu Y, Micklem D, Ruurs P, Shenk K, Sylvain C, ... ... Bennett M, et al. Anti-Tumor Activity of Immunoproteasome Selective Inhibitors. Blood. 110: 1599-1599. DOI: 10.1182/Blood.V110.11.1599.1599 |
0.448 |
|
| 2006 |
Demo SD, Aujay MA, Goldstein E, Laidig GJ, Parlati F, Lu Y, Shenk KD, Sun CM, Sylvain C, Woo TM, Zhou H, Bennett MK. Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity. Blood. 108: 4398-4398. DOI: 10.1182/Blood.V108.11.4398.4398 |
0.379 |
|
| 2006 |
Parlati F, Aujay MA, Demo SD, Goldstein ED, Jiang J, Kirk CJ, Laidig GJ, Lu Y, Muchamuel T, Shenk KD, Sylvain C, Sun CM, Woo TM, Zhou H, Bennett MK. Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders. Blood. 108: 4392-4392. DOI: 10.1182/Blood.V108.11.4392.4392 |
0.44 |
|
| 2006 |
Kirk CJ, Aujay MA, Ho M, Jiang J, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Woo TM, Sun CM, Sylvain C, Yang J, Zhou H, Bennett MK. Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome. Blood. 108: 3581-3581. DOI: 10.1182/Blood.V108.11.3581.3581 |
0.407 |
|
| 2006 |
Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, Leeuwen FWv, Orlowski RZ. The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance. Blood. 108: 3461-3461. DOI: 10.1182/Blood.V108.11.3461.3461 |
0.425 |
|
| 2005 |
Zhao H, Li CC, Pardo J, Chu PC, Liao CX, Huang J, Dong JG, Zhou X, Huang Q, Huang B, Bennett MK, Molineaux SM, Lu H, Daniel-Issakani S, Payan DG, et al. A novel E3 ubiquitin ligase TRAC-1 positively regulates T cell activation. Journal of Immunology (Baltimore, Md. : 1950). 174: 5288-97. PMID 15843525 DOI: 10.4049/Jimmunol.174.9.5288 |
0.335 |
|
| 2005 |
Kirk CJ, Bennett MK, Buchholz TJ, Demo SD, Ho MN, Jiang J, Laidig GJ, Lewis ER, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ. Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome. Blood. 106: 609-609. DOI: 10.1182/Blood.V106.11.609.609 |
0.426 |
|
| 2005 |
Bennett MK, Aujay MA, Buchholz TJ, Demo SD, Laidig GJ, Sun CM, Vallone MK, Woo T, Smyth MS. A Proteasome Specific Binding Assay for Quantitation of Constitutive and Immunoproteasome Active Sites. Blood. 106: 2472-2472. DOI: 10.1182/Blood.V106.11.2472.2472 |
0.406 |
|
| 2005 |
Demo SD, Buchholz TJ, Laidig GJ, Parlati F, Shenk KD, Smyth MS, Sullivan CM, Sun CM, Vallone MK, Woo T, Bennett MK. Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171. Blood. 106: 1588-1588. DOI: 10.1182/Blood.V106.11.1588.1588 |
0.444 |
|
| 2005 |
Ivancsits D, Nimmanapali R, Sun M, Shenk K, Demo SD, Bennett MK, Dalton WS, Alsina M. The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells. Blood. 106: 1575-1575. DOI: 10.1182/Blood.V106.11.1575.1575 |
0.367 |
|
| 2003 |
Hitoshi Y, Gururaja T, Pearsall DM, Lang W, Sharma P, Huang B, Catalano SM, McLaughlin J, Pali E, Peelle B, Vialard J, Janicot M, Wouters W, Luyten W, Bennett MK, et al. Cellular localization and antiproliferative effect of peptides discovered from a functional screen of a retrovirally delivered random peptide library. Chemistry & Biology. 10: 975-87. PMID 14583264 DOI: 10.1016/J.Chembiol.2003.09.009 |
0.633 |
|
| 2002 |
Pray TR, Parlati F, Huang J, Wong BR, Payan DG, Bennett MK, Issakani SD, Molineaux S, Demo SD. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 5: 249-58. PMID 12531181 DOI: 10.1016/S1368-7646(02)00121-8 |
0.326 |
|
| 2002 |
Kinsella TM, Ohashi CT, Harder AG, Yam GC, Li W, Peelle B, Pali ES, Bennett MK, Molineaux SM, Anderson DA, Masuda ES, Payan DG. Retrovirally delivered random cyclic Peptide libraries yield inhibitors of interleukin-4 signaling in human B cells. The Journal of Biological Chemistry. 277: 37512-8. PMID 12167667 DOI: 10.1074/Jbc.M206162200 |
0.348 |
|
| 2000 |
Masuda ES, Luo Y, Young C, Shen M, Rossi AB, Huang BC, Yu S, Bennett MK, Payan DG, Scheller RH. Rab37 is a novel mast cell specific GTPase localized to secretory granules. Febs Letters. 470: 61-4. PMID 10722846 DOI: 10.1016/S0014-5793(00)01288-6 |
0.304 |
|
| 1990 |
Edelman AM, Lin WH, Osterhout DJ, Bennett MK, Kennedy MB, Krebs EG. Phosphorylation of smooth muscle myosin by type II Ca2+/calmodulin-dependent protein kinase. Molecular and Cellular Biochemistry. 97: 87-98. PMID 2174101 DOI: 10.1007/Bf00231704 |
0.505 |
|
| 1990 |
Kennedy MB, Bennett MK, Bulleit RF, Erondu NE, Jennings VR, Miller SG, Molloy SS, Patton BL, Schenker LJ. Structure and regulation of type II calcium/calmodulin-dependent protein kinase in central nervous system neurons. Cold Spring Harbor Symposia On Quantitative Biology. 55: 101-10. PMID 1966761 DOI: 10.1101/Sqb.1990.055.01.013 |
0.492 |
|
| 1988 |
Bulleit RF, Bennett MK, Molloy SS, Hurley JB, Kennedy MB. Conserved and variable regions in the subunits of brain type II Ca2+/calmodulin-dependent protein kinase. Neuron. 1: 63-72. PMID 2856087 DOI: 10.1016/0896-6273(88)90210-3 |
0.5 |
|
| 1987 |
Bennett MK, Kennedy MB. Deduced primary structure of the beta subunit of brain type II Ca2+/calmodulin-dependent protein kinase determined by molecular cloning. Proceedings of the National Academy of Sciences of the United States of America. 84: 1794-8. PMID 3470758 DOI: 10.1073/Pnas.84.7.1794 |
0.521 |
|
| 1983 |
Kennedy MB, Bennett MK, Erondu NE. Biochemical and immunochemical evidence that the "major postsynaptic density protein" is a subunit of a calmodulin-dependent protein kinase. Proceedings of the National Academy of Sciences of the United States of America. 80: 7357-61. PMID 6580651 DOI: 10.1073/Pnas.80.23.7357 |
0.525 |
|
| Show low-probability matches. |
